Related Experiment Video

Updated: Jun 13, 2025

Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head
00:05

Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head

Published on: January 3, 2020

8.1K

Hyperinsulinemic Hypoglycemia Due to an Insulinoma in a 2-Year-Old Child

Lauren M Mitteer1,2, Lisa States2,3, Tricia Bhatti2,4

  • 1Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.

JCEM Case Reports
|September 17, 2024
PubMed

Insights

A rare pediatric insulinoma caused severe hypoglycemia in a child. Surgical removal of the pancreatic tumor successfully cured the condition, resolving the hyperinsulinism and eliminating the need for glucose monitoring.

Area of Science:

  • Pediatric Endocrinology
  • Surgical Oncology
  • Molecular Genetics

Background:

  • Insulinomas, rare insulin-secreting tumors, predominantly affect adults.
  • Pediatric hyperinsulinemic hypoglycemia (HI) presents diagnostic and therapeutic challenges.
  • Genetic testing for common HI-associated genes was negative in this case.

Observation:

  • A 26-month-old child presented with severe hypoglycemia, initially diagnosed as hyperinsulinemic hypoglycemia.
  • Despite 10 months of various HI therapies, the patient showed no significant improvement.
  • Imaging revealed a pancreatic lesion suggestive of an insulinoma.

Findings:

  • Histopathological review confirmed a benign, well-circumscribed insulinoma.
  • Surgical enucleation of the pancreatic lesion was performed.
  • Postoperative fasting tests confirmed resolution of hypoglycemia and hyperinsulinism.

Implications:

  • This case highlights the possibility of insulinoma in pediatric hyperinsulinemic hypoglycemia, even with negative genetic testing.
  • Successful surgical management can lead to a complete cure in pediatric insulinoma.
  • Early diagnosis and surgical intervention are crucial for favorable outcomes in pediatric insulinoma.

Keywords:
case reporthyperinsulinismhypoglycemiainsulinomapancreaspediatric

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.3K
Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
216
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
157
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.2K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
147